This Article Full Text Full Text (PDF) All Versions of this Article: 148/3/1306    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, C. S. Articles by Cheng, S.-y. Search for Related Content PubMed PubMed Citation Articles by Kim, C. S. Articles by Cheng, S.-y.

Gelsolin: A Novel Thyroid Hormone Receptor-ß Interacting Protein that Modulates Tumor Progression in a Mouse Model of Follicular Thyroid Cancer

Laboratory of Molecular Biology (C.S.K., F.F., H.Y., Y.K., S.C.), Center for Cancer Research, National Cancer Institute; and Laboratory of Cellular Biochemistry and Biology (J.A.H.), National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892-4264

Address all correspondence and requests for reprints to: Dr. Sheue-yann Cheng, National Cancer Institute, 37 Convent Drive, Room 5128, Bethesda, Maryland 20892-4264. E-mail: chengs{at}mail.nih.gov.

Follicular thyroid cancer (FTC) is known to metastasize to distant sites via hematogenous spread; however, the underlying pathways that contribute to metastasis remain unknown. Recent creation of a knockin mutant mouse that expresses a mutant thyroid hormone receptor-ß (TRß^PV/PV mouse) that spontaneously develops thyroid cancer with metastasis similar to humans has provided new opportunities to study contributors to FTC metastasis. This study evaluates the role of gelsolin, an actin-regulatory protein, in modulating the metastatic potential of FTC. Gelsolin was previously found by cDNA microarray analysis to be down-regulated in TRß^PV/PV mice as compared with wild-type mice. This study found an age-dependent reduction of gelsolin protein abundance in TRß^PV/PV mice as tumorigenesis progressed. Knockdown of gelsolin by small interfering RNA resulted in increased tumor cell motility and increased gelsolin expression by histone deacetylase inhibitor (trichostatin A) led to decreased cell motility. Additional biochemical analyses demonstrated that gelsolin physically interacted with TRß1 or PV in vivo and in vitro. The interaction regions were mapped to the C terminus of gelsolin and the DNA binding domain of TR. The physical interaction of gelsolin with PV reduced its binding to actin, leading to disarrayed cytoskeletal architectures. These results suggest that PV-induced alteration of the actin/gelsolin cytoskeleton contributes to increased cell motility. Thus, the present study uncovered a novel PV-mediated oncogenic pathway that could contribute to the local tumor progression and metastatic potential of thyroid carcinogenesis.

This article has been cited by other articles:

				G. Brabant Thyrotropin Suppressive Therapy in Thyroid Carcinoma: What Are the Targets? J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1167 - 1169. [Full Text] [PDF]